31,623 Shares in Aldeyra Therapeutics, Inc. $ALDX Bought by Ballast Inc.

Ballast Inc. acquired a new position in shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 31,623 shares of the biotechnology company’s stock, valued at approximately $121,000. Ballast Inc. owned about 0.05% of Aldeyra Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ALDX. Wealth Enhancement Advisory Services LLC acquired a new position in Aldeyra Therapeutics in the 1st quarter worth about $63,000. Capital Advisors Wealth Management LLC acquired a new position in Aldeyra Therapeutics in the 1st quarter worth about $62,000. CWM LLC increased its holdings in Aldeyra Therapeutics by 1,164.4% in the 1st quarter. CWM LLC now owns 19,244 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 17,722 shares in the last quarter. XTX Topco Ltd acquired a new position in Aldeyra Therapeutics in the 1st quarter worth about $134,000. Finally, Invesco Ltd. increased its holdings in Aldeyra Therapeutics by 1,575.7% in the 1st quarter. Invesco Ltd. now owns 501,137 shares of the biotechnology company’s stock worth $2,882,000 after purchasing an additional 471,231 shares in the last quarter. 59.71% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Stephen Machatha sold 22,073 shares of the firm’s stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $5.15, for a total transaction of $113,675.95. Following the completion of the sale, the insider owned 221,799 shares of the company’s stock, valued at $1,142,264.85. This trade represents a 9.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 8.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ALDX shares. Zacks Research raised Aldeyra Therapeutics to a “hold” rating in a report on Friday, August 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aldeyra Therapeutics in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $9.50.

Aldeyra Therapeutics Trading Down 2.4%

Shares of ALDX stock opened at $5.26 on Monday. The stock has a market cap of $315.07 million, a price-to-earnings ratio of -6.19 and a beta of 0.83. The stock has a 50-day moving average of $5.44 and a 200-day moving average of $4.02. Aldeyra Therapeutics, Inc. has a 1-year low of $1.14 and a 1-year high of $7.20.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.05. Sell-side analysts forecast that Aldeyra Therapeutics, Inc. will post -0.92 earnings per share for the current year.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.